ES2071479T3 - Derivados de indano. - Google Patents
Derivados de indano.Info
- Publication number
- ES2071479T3 ES2071479T3 ES92900941T ES92900941T ES2071479T3 ES 2071479 T3 ES2071479 T3 ES 2071479T3 ES 92900941 T ES92900941 T ES 92900941T ES 92900941 T ES92900941 T ES 92900941T ES 2071479 T3 ES2071479 T3 ES 2071479T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- alkyl
- hydroxy
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Fats And Perfumes (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE PRESENTAN DERIVADOS DEL TRANS-1-PIPERACINOINDANO-5 SUSTITUIDO QUE TIENEN LA FORMULA GENERAL I EN LA QUE X ES HALOGENO, TRIFLUOROMETIL, ALQUIL, ALQUILTIO, ALCILOXIDO, ALQUILSULFONIL, ALQUIL IDROGENO, O ALQUIL, ALQUENIL, CICLOALQUIL, O CICLOALQUILALQUIL INFERIOR, OPCIONALMENTE SUSTITUIDO CON HIDROXIDO, O R ES UN SUSTITUYENTE (A), EN EL QUE N ES UN ENTERO ENTRE 1 Y 6; U ES CH O N; Y ES CH2, O, S, O N-R1, SIENDO R1 HIDROGENO O CICLOALQUIL, CICLOALQUILMETIL, ALQUIL O ALQUENIL OPCIONALMENTE SUSTITUIDO CON HIDROXIDO O UN GRUPO DE FENIL OPCIONALMENTE SUSTITUIDO; W ES O O S; Z ES -(CH2)4-, (B), (C), EN DONDE R2 Y R3 ES HIDROGENO O ALQUIL INFERIOR, -CH = CH-, -CH = CH OPCIONALMENTE SUSTITUIDO, 1,2-C6H4CH2(PARA FORMAR UNA QUINAZOLIDINONA O UN SISTEMA DE ANILLO DE TIONA) O 1,2-C6H4CO ORMAR UN SISTEMA DE ANILLO DE QUINOZOLIDINDION O UN SISTEMA DE ANILLO DE TIOXOQUINAZOLIDINDION); Y AR ES UN ANILLO DE FENIL OPCIONALMENTE SUSTITUIDO, DE TIOFENO O DE FURANO; LOS COMPUESTOS SON ANTAGONISTAS SELECTIVOS DEL 5-HT2 QUE ACTUAN CENTRALMENTE Y POR LO TANTO UTILES EN EL TRATAMIENTO DE LA ANSIEDAD, DEPRESION, DESORDENES DEL SUEÑO, SINTOMAS NEGATIVOS DE ESQUIZOFRENIA Y MIGRAÑA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK286990A DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Indanderivater |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2071479T3 true ES2071479T3 (es) | 1995-06-16 |
Family
ID=8116621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92900941T Expired - Lifetime ES2071479T3 (es) | 1990-12-04 | 1991-11-28 | Derivados de indano. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0560868B1 (es) |
JP (1) | JP3245418B2 (es) |
KR (1) | KR930702980A (es) |
AT (1) | ATE121294T1 (es) |
AU (1) | AU653375B2 (es) |
CA (1) | CA2097715C (es) |
DE (1) | DE69109132T2 (es) |
DK (2) | DK286990D0 (es) |
ES (1) | ES2071479T3 (es) |
FI (1) | FI105685B (es) |
HK (1) | HK122995A (es) |
IE (1) | IE914076A1 (es) |
IL (1) | IL100164A (es) |
NO (1) | NO179947C (es) |
NZ (1) | NZ240734A (es) |
PT (1) | PT99673B (es) |
WO (1) | WO1992010192A1 (es) |
ZA (1) | ZA919563B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
DK78692D0 (da) * | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | Dimere piperidin- og piperazinderivater |
SK94393A3 (en) * | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
JP2000514060A (ja) * | 1996-07-01 | 2000-10-24 | シェーリング コーポレイション | ムスカリン様アンタゴニスト |
US5935958A (en) * | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
IS7282A (is) * | 2001-12-21 | 2004-05-21 | H. Lundbeck A/S | Amínóindan afleiður sem serótónín og noradrenalínupptökuhindrar |
EP1458704A1 (en) * | 2001-12-21 | 2004-09-22 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
FR2883876B1 (fr) * | 2005-03-30 | 2007-05-04 | Servier Lab | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
PL2720989T3 (pl) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ196284A (en) * | 1980-02-29 | 1983-12-16 | Kefalas As | 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions |
GB8427125D0 (en) * | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
-
1990
- 1990-12-04 DK DK286990A patent/DK286990D0/da not_active Application Discontinuation
-
1991
- 1991-11-22 IE IE407691A patent/IE914076A1/en not_active IP Right Cessation
- 1991-11-26 NZ NZ240734A patent/NZ240734A/en not_active IP Right Cessation
- 1991-11-27 IL IL10016491A patent/IL100164A/en not_active IP Right Cessation
- 1991-11-28 KR KR1019930701680A patent/KR930702980A/ko not_active Application Discontinuation
- 1991-11-28 DK DK92900941.3T patent/DK0560868T3/da active
- 1991-11-28 ES ES92900941T patent/ES2071479T3/es not_active Expired - Lifetime
- 1991-11-28 EP EP92900941A patent/EP0560868B1/en not_active Expired - Lifetime
- 1991-11-28 AT AT92900941T patent/ATE121294T1/de not_active IP Right Cessation
- 1991-11-28 CA CA002097715A patent/CA2097715C/en not_active Expired - Fee Related
- 1991-11-28 WO PCT/DK1991/000358 patent/WO1992010192A1/en active IP Right Grant
- 1991-11-28 DE DE69109132T patent/DE69109132T2/de not_active Expired - Fee Related
- 1991-11-28 JP JP50028192A patent/JP3245418B2/ja not_active Expired - Fee Related
- 1991-11-28 AU AU89599/91A patent/AU653375B2/en not_active Ceased
- 1991-12-03 PT PT99673A patent/PT99673B/pt not_active IP Right Cessation
- 1991-12-04 ZA ZA919563A patent/ZA919563B/xx unknown
-
1993
- 1993-06-03 NO NO932024A patent/NO179947C/no not_active IP Right Cessation
- 1993-06-03 FI FI932541A patent/FI105685B/fi active
-
1995
- 1995-07-27 HK HK122995A patent/HK122995A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU653375B2 (en) | 1994-09-29 |
JP3245418B2 (ja) | 2002-01-15 |
IE914076A1 (en) | 1992-06-17 |
AU8959991A (en) | 1992-07-08 |
FI105685B (fi) | 2000-09-29 |
PT99673B (pt) | 1999-05-31 |
ATE121294T1 (de) | 1995-05-15 |
HK122995A (en) | 1995-08-04 |
FI932541A (fi) | 1993-07-23 |
JPH06503073A (ja) | 1994-04-07 |
NO932024D0 (no) | 1993-06-03 |
IL100164A (en) | 1996-06-18 |
DK286990D0 (da) | 1990-12-04 |
NO179947C (no) | 1997-01-15 |
DK0560868T3 (da) | 1995-10-02 |
FI932541A0 (fi) | 1993-06-03 |
NZ240734A (en) | 1994-02-25 |
DE69109132T2 (de) | 1995-08-31 |
EP0560868B1 (en) | 1995-04-19 |
CA2097715A1 (en) | 1992-06-05 |
EP0560868A1 (en) | 1993-09-22 |
PT99673A (pt) | 1992-10-30 |
CA2097715C (en) | 2003-04-15 |
KR930702980A (ko) | 1993-11-29 |
WO1992010192A1 (en) | 1992-06-25 |
ZA919563B (en) | 1992-08-26 |
NO179947B (no) | 1996-10-07 |
NO932024L (no) | 1993-07-30 |
DE69109132D1 (de) | 1995-05-24 |
IL100164A0 (en) | 1992-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE115576T1 (de) | Neue indolderivate. | |
ES2071479T3 (es) | Derivados de indano. | |
ES2064974T3 (es) | Nuevos derivados de 3-arilindol y 3-arilindazol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 560868 Country of ref document: ES |